# Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock

> **NCT02191475** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Abdominal Infection

## Interventions

- **DRUG:** glycopeptide plus carbapenem
- **DRUG:** Haizheng Li Xing ® plus tazocin ®

## Key facts

- **NCT ID:** NCT02191475
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2014-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02191475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02191475, "Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02191475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*